The use of the anti-vascular drug 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) in combination with the HIF-1α inhibitor Digoxin inhibited tumor growth and stimulated immunity in a melanoma model, demonstrating a significant increase in the percentage of CD8 cytotoxic lymphocytes and NK cells [79]. The gene discussed is CD8A; the disease is neoplasm.